EMA Adopts Final Guideline on Clinical Considerations for Evaluating Biosimilarity

Drug Industry Daily
A A
The European Medicines Agency wants biosimilars makers to use pharmacodynamic markers alongside pharmacokinetic data to demonstrate biosimilarity.

To View This Article:

Login

Subscribe To Drug Industry Daily